SANA Sana Biotechnology, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1770121 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY36.3%
TTM EPS YoY45.8%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-79.5%
ROA-36.8%
ROIC (approx.)-109.1%
Asset turnover—
Leverage & solvency
Liabilities / assets52.0%
Debt / equity0.00x
Current ratio1.77x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.95x
Accruals ratio-1.9%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | — | — |
| R&D expense | $131.98M | $215.67M |
| SG&A expense | $44.30M | $64.04M |
| Operating income | -$250.32M | -$272.72M |
| Income tax | $0 | — |
| Net income | -$244.17M | -$266.76M |
| EBITDA | -$237.52M | -$257.22M |
| EPS (basic) | -0.96 | -1.16 |
| EPS (diluted) | -0.96 | -1.16 |
| Weighted avg. shares (diluted) | 253.23M | 230.89M |
| Balance sheet | ||
| Cash & equivalents | $71.87M | $131.40M |
| Short-term investments | $66.51M | $24.93M |
| Current assets | $148.68M | $160.81M |
| PP&E, net | $26.91M | $77.31M |
| Goodwill | $140.63M | $140.63M |
| Intangibles | $59.20M | $59.20M |
| Total assets | $416.89M | $501.02M |
| Current liabilities | $78.73M | $45.43M |
| Total liabilities | $256.01M | $250.52M |
| Shareholders' equity | $160.88M | $250.50M |
| Shares outstanding | 266.73M | 223.92M |
| Cash flow statement | ||
| Operating cash flow | -$143.83M | -$223.15M |
| Capital expenditure | $938,000 | $33.43M |
| Free cash flow | -$144.77M | -$256.58M |
| Investing cash flow | -$40.24M | $17.45M |
| Financing cash flow | $128.73M | $199.75M |
| Depreciation & amortization | $12.80M | $15.50M |
| Stock-based compensation | $25.46M | $37.68M |
Free plan shows the latest 2 periods; Pro shows all 7 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.